ClinicalTrials.gg
CompletedNCT04584736Updated Dec 1, 2021

To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia

A Phase 3 interventional study of Livalo, Ezetrol in Primary Hypercholesterolemia, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-12-01.

Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jun 2019, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
8th of 19
283 · median 200
Started
2019
with 1 other
Phase 3
9 of 19
none open now
Registered
18th of 19
by date
Lead sponsor
4 of 19
JW Pharmaceutical

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 3, and was the 18th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.

Read the detailed description

A Multi-center, Randomized, Double-blinded, Active-controlled, Factorial Design Phase 3 Clinical Trial

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with primary hypercholesterolemia

Exclusion criteria

Exclusion Criteria:

  • The subject not meet the specified LDL-C level
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Livalo 2mg, Ezetrol 10mg

    Pitavastatin 2mg, Ezetimibe 10mg

    Drug: Livalo, Ezetrol

  • Active comparator
    Livalo 2mg

    Pitavastatin 2mg

    Drug: Livalo, Ezetrol

  • Experimental
    Livalo 4mg, Ezetrol 10mg

    Pitavastatin 4mg, Ezetimibe 10mg

    Drug: Livalo, Ezetrol

  • Active comparator
    Livalo 4mg

    Pitavastatin 4mg

    Drug: Livalo, Ezetrol

Interventions

  • DrugLivalo, Ezetrol

    Drug pages: Pitavastatin · Ezetimibe

    Pitavastatin+Ezetimibe Pitavastatin

    Also known as: Pitavastatin, Ezetimibe

06

What researchers measure

Primary outcomes

  1. % change in LDL-C level from baseline at Week 8

    change in LDL-C level

    Time frame: Week 8

Secondary outcomes

  1. Change in LDL-C level from baseline at Week 4 and Week 8

    change in LDL-C level

    Time frame: Week 4 and Week 8

07

Study locations

1 site
  • Gangdong Sacred Heart Hospital
    Seoul, Korea 134-701, Korea, Republic of
08

References and documents

Publications

  • Jeong HS, Hong SJ, Cho JM, Han KH, Cha DH, Jo SH, Kang HJ, Choi SY, Choi CU, Cho EJ, Jeong YH, Gwon HC, Kim BK, Lee SY, Kim SH, Ahn JC, Hong YJ, Kim WS, Woo SI, Park TH, Han KR. A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia. Clin Ther. 2022 Oct;44(10):1310-1325. doi: 10.1016/j.clinthera.2022.09.001. Epub 2022 Oct 12. PubMed 36241463 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Jul 2020, 13 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 13 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2020
First posted
Oct 14, 2020
StartActual
Jun 11, 2019
Primary completionActual
Jul 16, 2020
CompletionActual
Oct 12, 2020
Last update
Dec 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04584736
Lead sponsor
JW Pharmaceutical
Responsible party
Sponsor
First posted
Oct 14, 2020
Start date
Jun 11, 2019
Primary completion
Jul 16, 2020
Completion
Oct 12, 2020
Last update
Dec 1, 2021

Study contacts

dongryeong lee, Manager
study chair · +82-2-840-6982

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pitavastatin · Ezetimibe

Start the discussion